MCRB - Seres Therapeutics, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
7,128
7,128
144,927
33,215
34,505
Operating expenses
Research development
172,920
172,920
141,891
90,570
80,141
Selling general and administrative
79,694
79,694
69,261
30,775
24,748
Total operating expenses
253,618
253,618
209,420
121,345
104,889
Operating income or loss
-246,490
-246,490
-64,493
-88,130
-70,384
Interest expense
6,020
6,020
2,910
2,924
502
Total other income/expenses net
-705
-705
-1,045
981
-426
Income before tax
-250,157
-250,157
-65,578
-89,127
-70,279
Income from continuing operations
-250,157
-250,157
-65,578
-89,127
-70,279
Net income
-250,157
-250,157
-65,578
-89,127
-70,279
Net income available to common shareholders
-250,157
-250,157
-65,578
-89,127
-70,279
Basic EPS
-
-2.31
-0.72
-1.12
-1.24
Diluted EPS
-
-2.31
-0.72
-1.12
-1.24
Basic average shares
-
108,077
91,703
79,789
56,649
Diluted average shares
-
108,077
91,703
79,789
56,649
EBITDA
-
-244,137
-62,668
-86,203
-69,777